InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Insider track record
OtherDisclosed buys
2
Disclosed sells
1
T+90 hit rate
100%
T+90 mean return
+41.8%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Dexcel Pharma Technologies Ltd.. Officer active across 2 companies, notably Protalix BioTherapeutics, Inc.. In total, 3 reports have been recorded. Split: 2 buys · 1 sell. Total volume traded: €20.2m. History available since 2 June 2021. The latest transaction was filed on 10 November 2022 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Dexcel Pharma Technologies Ltd.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
4,000,000 shares@ US$5.0099.4% of flowCommon SharesSEC:0001104659-22-117847:0
Canonical exit: 8 Feb 2023 (T+90)
31,685 shares@ US$3.82890.0005% mcap100.0% of flowCommon SharesSEC:0001104659-22-049930:0
Canonical exit: 21 Jul 2022 (T+90)
61,211 shares@ US$2.5576100.0% of flowCommon StockSEC:0001104659-21-076488:0
3 of 3 declarations
About Dexcel Pharma Technologies Ltd.
Dexcel Pharma Technologies Ltd. is a declarant linked to Roivant Sciences Ltd. and Protalix BioTherapeutics, Inc. In the sampled recent filings, buys total EUR 20072967 and sells total EUR 256437, covering the period from 2021-06-03 to 2022-11-14. The total number of filings is 4, and the modal transaction nature shown is Acquisition.
